儿童穿透性克罗恩病并发症早期抗TNF治疗的安全性与有效性
这项多中心回顾性研究纳入2007至2021年203例住院的儿童克罗恩病合并腹腔内穿透性并发症患者,其中43%在诊断后30天内接受早期抗TNF治疗。早期抗TNF未增加感染性或非感染性严重不良事件及手术风险,但与1年内联合缓解率升高相关;在接受经皮引流的患者中,早期抗TNF与手术风险降低相关。
要点
- 早期抗TNF未增加90天内感染性或CD相关严重不良事件风险。
- 早期抗TNF与1年内临床-生化-无激素联合缓解率升高相关(HR 1.65)。
- 接受经皮引流的患者中,早期抗TNF与手术风险降低相关。
核心结论
- 儿童穿透性克罗恩病并发症早期抗TNF治疗未增加感染性或CD相关严重不良事件。
- 在接受经皮引流的患者中,早期抗TNF与手术风险降低相关。
研究设计与样本
- 多中心回顾性研究,纳入2007至2021年诊断为腹腔内穿透性并发症的儿童(年龄6岁及以上)。
- 共203例患者,中位年龄16岁,50%为女孩;87例(43%)在诊断后30天内接受早期抗TNF治疗。
- 采用逆概率治疗加权Kaplan-Meier曲线和按经皮引流状态分层的Cox比例风险模型比较结局。
主要发现
- Cox分析显示早期抗TNF与感染性严重不良事件、CD相关严重不良事件或手术无显著关联。
- 早期抗TNF与1年内联合临床-生化-无激素缓解率升高相关(HR 1.65,95%CI 1.20-2.27)。
- 接受早期抗TNF联合经皮引流的患者与仅经皮引流者相比,无事件生存率分别为58%和15%(log-rank P=0.04)。
临床怎么用
- 对于儿童克罗恩病合并腹腔内穿透性并发症,可在多学科治疗框架下考虑早期启动抗TNF治疗。
- 接受经皮引流的患者早期抗TNF可能降低手术风险。
局限性
- 为回顾性研究,需要前瞻性研究及标准化治疗方案进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Children with Crohn's disease (CD) who develop internally penetrating complications (IPCs; abscesses and inflammatory masses) are at high risk of surgery and other adverse events. Early anti-tumor-necrosis-factor therapy (anti-TNF) improves outcomes among children with CD and anti-TNF initiation soon after IPC resolution decreases surgical risk. We aimed to evaluate the safety and effectiveness of early anti-TNF therapy among children hospitalized with active IPCs. METHODS: We conducted a multicenter retrospective study of children (age 6 years and older) diagnosed with IPCs from 2007 to 2021. The exposure was anti-TNF within 30 days of IPC diagnosis. Outcomes included (i) infectious serious adverse events (iSAE) within 90 days, (ii) noninfectious CD-related SAE (cdSAE), (iii) CD-related surgery, and (iv) combined clinical-biochemical-corticosteroid-free remission within 1 year. Outcomes were compared by inverse-probability-of-treatment-weighted Kaplan-Meier curves (log-rank test) and Cox proportional hazards models stratified by percutaneous drainage (PD) status. RESULTS: Among 203 patients (median age 16 years, 50% girls), 87 (43%) received early anti-TNF within 30 days of IPC diagnosis. In Cox analyses, early anti-TNF was not linked to iSAE, cdSAE, or surgeries, but was associated with increased combined clinical-biochemical-corticosteroid-free remission (hazard ratio 1.65, 95% CI 1.20-2.27). However, surgical risk differed by PD status: patients receiving early anti-TNF and PD had lower risk versus PD alone (event-free survival 58% vs 15%, log-rank P = 0.04). DISCUSSION: Early anti-TNF therapy in children with IPCs was not associated with iSAE or cdSAE. Notably, in those undergoing PD, early anti-TNF was associated with decreased surgeries. These findings support early anti-TNF initiation within a multidisciplinary treatment framework. Prospective studies with standardized treatment protocols are needed.
引用
- Constant BD, Feng Y, Huang J, et al. The Safety and Effectiveness of Early Anti-tumor-necrosis-factor Therapy for Penetrating Crohn's Disease Complications in Children. Am J Gastroenterol. 2026. PMID: 42378115. doi:10.14309/ajg.0000000000004104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。